Sanne de Bruin

82 Chapter 3 Table S1. Difference between respondents with and without a massive transfusion protocol (continued) Massive transfusion protocol (N= 209) No massive transfusion protocol (N= 192) P-value 6 : 3 : 1 (red blood cells : plasma : platelets concentrate) 10(5%) 13(7%) Other (please specify) 29(14%) 9(5%) Whole blood 0(0%) 2(1%) How do you correct a plasmatic coagulopathy (INRx1.5 reference value or prolonged clotting time with TEG or ROTEM) in critically ill patients with massive blood loss who used vitamin K antagonists? Vitamin K 144(69%) 130(68%) 0.882 Prothrombin complex (Cofact/Octoplex/Beriplex) 178(85%) 136(71%) 0.001 Plasma 114(55%) 132(69%) 0.005 Nothing 1(0%) 2(1%) 0.941 How do you correct a plasmatic coagulopathy in critically ill patients with massive blood loss who used direct oral anti-coagulants(DOACs)? Vitamin K 45(22%) 47(24%) 0.56 Prothrombin complex (Cofact/Octoplex/Beriplex) 155(74%) 118(61%) 0.009 Plasma 119(57%) 137(71%) 0.004 Recombinant factor VIIa (Novoseven/Eptacog Œ±) 32(15%) 36(19%) 0.433 Idarucizumab (for dabigatran) 119(57%) 75(39%) 0.001 Andexanet (for rivaroxaban or apixaban) 51(24%) 33(17%) 0.099